Početna › Kronična limfocitna leukemija › Illinois
Kliničke studije za Kronična limfocitna leukemija u državi Illinois
17 studija za Kronična limfocitna leukemija traži sudionike na lokacijama u državi Illinois.
Gradovi u državi Illinois
- Chicago14 studija
- Evanston4 studija
- Springfield4 studija
- Waukegan4 studija
- Danville3 studija
- Champaign3 studija
- Decatur3 studija
- Charleston3 studija
Službeni tekst studije (engleski)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- i još 27
U tijeku regrutacijaFaza 3
Od 65 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- i još 54
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Rush-Copley Medical Center, Aurora
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- i još 28
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Northwestern University, Chicago
- Illinois Cancer Specialists (Niles) Usor, Niles
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Northwestern University, Chicago
- Midwestern Regional Medical Center, Zion
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- University of Chicago Medical Center, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06973187Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Chicago, Zion
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT04588922A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- The David and Etta Jonas Center for Cellular Therapy, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT06528301ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Orchard Healthcare Research, Skokie
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 11. kol 2026. · NCT07342478A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Northwestern University, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT05131022Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
U tijeku regrutacijaFaza 1
Od 13 godina i više · Oba spola · Ažurirano 5. svi 2026. · NCT04771572The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
U tijeku regrutacijaFaza 1/2
Od 12 do 95 godina · Oba spola · Ažurirano 15. tra 2026. · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Springfield Clinic - First /ID# 270145, Springfield
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. tra 2026. · NCT06428019A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- The University of Chicago Medical Center, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. ožu 2026. · NCT04830137A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Northwestern University, Chicago
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 2. ožu 2026. · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Northwestern University, Chicago
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 2. ožu 2026. · NCT06876649AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Northwestern Memorial Hospital, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. pro 2025. · NCT05602363Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.